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ABSTRACT 
The aims of this study were to get an overall view of 25-hydroxyvitamin D 
(25[OH]D) concentrations in healthy Finnish children, to find the major factors 
influencing the levels, and to find if there are differences in 25(OH) concentrations 
already at birth or later in childhood between children who develop islet 
autoimmunity (IA) or type 1 diabetes (T1D) and autoantibody negative children. 
The study population comprised of children born in 1994-2004 participating in 
Type 1 Diabetes Prediction and Prevention study (DIPP) clinics in Turku, Oulu and 
Tampere University Hospitals, Finland. 
In this study we showed there was a marked increase in the 25(OH)D 
concentrations in healthy children, who were over the age of two years, in year 2003. 
Seasonal variation was significant, and it remained the same after year 2003. A large-
scale program for vitamin D fortification of dairy products and other foodstuffs was 
begun in Finland in 2003.  
The median 25(OH)D concentrations were lowest at birth and highest at the age 
of six months, and they were not associated with the development of IA or T1D 
during childhood in follow-up lasting up to 14 years. The concentrations were 
associated with geographical location, sampling year and month, age of the child and 
for the samples taken at birth also with maternal age and maternal intake of vitamin 
D during pregnancy.    
KEYWORDS: type 1 diabetes, serum, 25-hydroxyvitamin D, vitamin D, islet 
autoimmunity, pregnancy, neonate, infant, child, Finland  
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TIIVISTELMÄ 
Tutkimuksen tavoitteina oli luoda yleiskatsaus terveiden suomalaislasten seerumin 
25-hydroksi-D-vitamiinin (25[OH]D) pitoisuuksista, pitoisuuksiin vaikuttavien 
tekijöiden kartoittaminen, ja sen selvittäminen eroavatko 25(OH)D pitoisuudet 
syntymähetkellä tai myöhemmin lapsuudessa niillä lapsilla, joille kehittyy 
saarekesoluvasta-aineita (IA) tai jotka sairastuvat tyypin 1 diabetekseen (T1D), kun 
heitä verrataan vasta-ainenegatiivisiin lapsiin.  
Työssä tutkittiin vuosina 1994 - 2004 syntyneitä lapsia, jotka osallistuivat tyypin 
1 diabeteksen ehkäisemiseen ja ennustamiseen tähtäävään DIPP-tutkimukseen 
Turun, Oulun ja Tampereen yliopistosairaaloissa.  
Terveillä yli kaksivuotiailla lapsilla seerumin 25(OH)D pitoisuudet olivat 
merkittävästi korkeammat vuodesta 2003 alkaen kuin sitä ennen. Vuoden-
aikavaihtelu oli huomattavaa ja pysyi samanlaisena vuoden 2003 jälkeen. Vuonna 
2003 Suomessa aloitettiin maitotuotteiden ja muutamien muiden elintarvikkeiden 
laajamittainen D-vitaminointiohjelma. 
Tutkimuksessa havaittiin, että seerumin 25(OH)D-mediaanipitoisuudet ovat 
alimmillaan syntymähetkellä ja korkeammillaan puolivuotiailla lapsilla, mutta 
pitoisuudet eivät assosioituneet IA:n tai T1D:n kehittymiseen lapsilla. Pitoisuuksiin 
vaikuttivat maantieteellinen sijainti, näytteenottovuosi ja –kuukausi, lapsen ikä sekä 
syntymäpitoisuuteen myös äidin ikä ja raskaudenaikainen D-vitamiininsaanti.      
AVAINSANAT: tyypin 1 diabetes, seerumi, 25-hydroksi-D-vitamiini, D-vitamiini, 
raskaus, vastasyntynyt, lapsi, lastentaudit, Suomi   
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Abbreviations 
1,25(OH)2D 1,25-dihydroxyvitamin D, calcitriol 
7-DHC 7-dehydrocholesterol 
25(OH)D 25-hydroxyvitamin D, calcidiol 
BMI body mass index 
CI  confidence interval 
CV coefficient of variability 
DASP Diabetes Autoantibody Standardization Program 
DBP vitamin D binding protein 
DEQAS The External Vitamin D Assessment Scheme 
DIPP Type 1 Diabetes Prediction and Prevention study 
DNA deoxyribonucleic acid 
EIA enzyme immunoassay 
GADA antibodies to 65 kilodalton isoform of glutamic acid decarboxylase 
HLA  human leukocyte antigen 
IA islet autoimmunity 
IA-2A antibodies to the protein tyrosine phosphatase related IA-2 protein 
IAA  insulin autoantibodies 
ICA  islet cell autoantibodies 
IQR inter-quartile range 
IU international unit 
IVGTT intravenous glucose tolerance test 
JDFU Juvenile Diabetes Foundation units 
PCR polymerase chain reaction 
PTH parathyroid hormone 
RU relative units 
SD standard deviation 
SNP single nucleotide polymorphism 
T1D type 1 diabetes  
TEDDY The Environmental Determinants of Diabetes in the Young study 
UL upper limit for daily intake 
UV ultraviolet 
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VDR vitamin D receptor 
ZnT8A antibody to pancreas-specific zinc transporter 8 
 
  
 10
List of Original Publications 
This dissertation is based on the following original publications, which are referred 
to in the text by their Roman numerals: 
I Mäkinen Marjaana, Simell Ville, Mykkänen Juha, Ilonen Jorma, Veijola 
Riitta, Knip Mikael, Simell Olli, Toppari Jorma, and Hermann Robert. An 
increase in serum 25-hydroxyvitamin D concentrations preceded a plateau in 
type 1 diabetes incidence in Finnish children. Journal of Clinical 
Endocrinology & Metabolism, 2014; 99(11): E2353-2356.  
II  Mäkinen Marjaana, Mykkänen Juha, Koskinen Maarit, Simell Ville, Veijola 
Riitta, Hyöty Heikki, Ilonen Jorma, Knip Mikael, Simell Olli, and Toppari 
Jorma. Serum 25-hydroxyvitamin D concentrations in children with HLA-
conferred disease susceptibility progressing to autoimmunity and clinical type 
1 diabetes. Journal of Clinical Endocrinology & Metabolism, 2016; 
101(2):723-729. 
III  Mäkinen Marjaana, Löyttyniemi Eliisa, Koskinen Maarit, Vähä-Mäkilä Mari, 
Siljander Heli, Nurmio Mirja, Mykkänen Juha, Virtanen Suvi, Simell Olli, 
Hyöty Heikki, Ilonen Jorma, Knip Mikael, Veijola Riitta, and Toppari Jorma. 
Serum 25-hydroxyvitamin D concentrations at birth in children screened for 
HLA-DQB1 risk for type 1 diabetes. Journal of Clinical Endocrinology & 
Metabolism, 2019; 104(6): 2277-2285 
The list of original publications have been reproduced with the permission of the 
copyright holders. 
 
 11 
1 Introduction 
Type 1 diabetes (T1D) is a chronic disease caused by inadequate endogenous 
production of insulin and characterized by impaired glucose metabolism. This 
severe, life-threatening disease occurs all around the world, but the highest incidence 
is in Finland. The reason for the high incidence is unknown as is the aetiology of the 
disease. 
Vitamin D is known to have important roles in human health. Serum level of the 
storage form of vitamin D, 25-hydroxyvitamin D (25[OH]D), is the best indicator to 
assess vitamin D deficiency, insufficiency, hypovitaminosis, adequacy, and toxicity, 
since it reflects both the intake of vitamin D from food and supplements, and its 
synthesis from precursors in the skin after exposure to sun or other sources of 
ultraviolet light. However, due to the angle of the sun, no vitamin D is produced 
subcutaneously from October to March to the north from 37 ºN. Finland is located 
far up in the north, between 60 ºN and 70 ºN, and several studies have shown low 
serum 25(OH)D levels in the Finnish population, especially during winter. 
The aim of this study was to assess the possible connection between serum 
25(OH)D concentration and the risk of T1D in children. 
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2 Review of the Literature 
2.1 Epidemiology of type 1 diabetes in children 
Type 1 diabetes (T1D) is an incurable autoimmune disease caused by selective 
destruction of the insulin-producing β-cells in the islets of Langerhans in pancreas. 
It is of particular interest in Finland, where the overall incidence of T1D in children 
is the highest in the world and has risen to 60.9 per 100 000 people per year 
(Patterson et al., 2019).   
The incidence of T1D has been increasing world-wide since the 1950s but the 
trend is finally abating in some countries with high incidences, such as Finland, 
where the increase in incidence levelled off in 2005 and Norway, where this 
happened in 2007 (Patterson et al., 2019).  The incidence rate in Finland is slightly 
different in different age groups (Harjutsalo et. al., 2013), but the trend can be seen 
in all of them, as seen in Fig.1. 
In Finland T1D is slightly more common in males than in females, unlike in 
many other countries (Diabetes Epidemiology Research International Group, 1988), 
but rate of increase in incidence is now higher in boys than in girls globally in 10- to 
14-year age group (Patterson et al., 2019). 
Review of the Literature 
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Figure 1.  T1D incidence per 100 000 per year in Finnish children during 1980-2011 in different 
age groups (Harjutsalo et al., 2013; Harjutsalo et al., 2008): Incidence for 0-4 year-old 
children in light grey, for  5-9 year-olds in grey, for 10-14 year-olds in dark grey and for 
all age groups, 0-14 years, in black.   
2.2 Natural course of T1D in children 
The classical model of the natural course of type 1 diabetes presented over 30 years 
ago (Eisenbarth, 1986) is still essentially valid (Greenbaum et al., 2018) with its six 
stages: 1) genetic susceptibility, 2) triggering of autoimmunity, 3) active immunity, 
4) progressive loss of glucose-stimulated insulin release, 5) overt T1D, 6) complete 
β-cell destruction.   
2.2.1 Genetic susceptibility 
The process leading to T1D in children is thought to commence with a genetic 
susceptibility (Davies et al., 1994). Increased genetic risk consists mainly of human 
leukocyte antigen (HLA) factors, so that HLA-DR/DQ region is the major 
determinant of the genetic risk for T1D, despite over 50 risk affecting loci have been 
found in other regions (Ilonen et al., 2016). A simplified classification of HLA-
DQB1 genotypes used in risk assessment was to divide them into high, moderate, 
low and decreased risk (Veijola et al., 1996). Increased genetic risk is not an absolute 
requirement, as even the highest risk is found only in 22 % of the patients and 2 % 
of healthy controls (Ilonen et al., 2016), and some children with so called protective 
HLA alleles may develop T1D as well (Huopio et al., 2016). Nevertheless, having a 
Marjaana Mäkinen 
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first-degree relative with T1D makes it 10 times more likely to develop the disease 
(Hippich et al., 2019). 
2.2.2 Triggering of autoimmunity  
Several environmental factors have been linked with the progression towards the 
second state, islet autoimmunity (IA). The studies are somewhat controversial, but 
the most prominentfactors are enteroviruses (Dotta et al., 2007), such as 
coxsackievirus (Sioofy-Khojine et al., 2018), and their close relatives, 
parechoviruses (Nilsson et al., 2013). Some early dietary factors, such as omega-3-
fatty acids (Norris et al., 2007), have been associated with lower risk of IA, while 
others, such as cow milk components  (Vaarala et al., 2012) and the age when a child 
was first exposed to cereals (Norris et al., 2014), or gluten (Uusitalo et al., 2018) 
have been implicated as potential triggers. Despite many efforts, there have been no 
successful interventions in preventing the development of IA (Couper et al., 2014). 
In some children endogenous events may be enough to initiate autoimmunity without 
any environmental triggers (Todd, 2010). The process begins many months or even 
years before any symptoms can be detected (Ziegler et al., 2013).   
2.2.3 Active immunity 
Islet autoimmunity can be detected in serum samples with autoantibody 
measurement. The first autoantibody found to have a connection with T1D was 
discovered already in 1970’s, and it was an IgG class non-specific islet cell 
autoantibody (ICA) (Bottazzo et al., 1974).  Biochemical islet autoantibodies were 
discovered later, these include insulin autoantibody (IAA) (Atkinson et al., 1986), 
antibody to the protein tyrosine phosphatase related IA-2 protein (IA-2A) (Bonifacio 
et al,. 1995), antibody to 65 kilodalton isoform of glutamic acid decarboxylase 
(GADA) (Baekkeskov et al., 1990) and antibody to pancreas-specific zinc 
transporter 8 (ZnT8A) (Wenzlau et al., 2007). Autoantibodies are produced by B 
cells with the help of follicular T helper cells (Serr et al., 2016). Young age at 
seroconversion and positivity for multiple autoantibodies are associated with high 
risk for disease progression (H. T. A. Siljander et al., 2009). IA is a dynamic process 
as both positive and inverse seroconversions may occur during follow-up (Knip et 
al., 2010), but risk for developing T1D remains elevated after seroconversion even 
if individual autoantibodies revert (Vehik et al., 2016). 
Review of the Literature 
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2.2.4 Progressive loss of glucose-stimulated insulin release 
First signs of insulitis development and advanced β-cell destruction is reduced early 
insulin response, detected via intravenous glucose tolerance test (IVGTT) (Koskinen 
et al., 2016). The velocity of the process and the severity of insulitis at disease onset 
are dependent on the age of the child (Rodriguez-Calvo et al., 2018). 
2.2.5 Overt T1D 
T1D is diagnosed when fasting blood glucose is 7.0 mmol/l or above, a random blood 
glucose is 11.0 mmol/l or above with symptoms of hyperglycemia, or two-hour 
plasma glucose level is 11.1 mmol/l or above in standardized oral glucose tolerance 
test (American Diabetes Association, 2018). T1D is generally characterized by 
insulin deficiency leading to hyperglycemia. Polydipsia and polyuria are often the 
first tangible symptoms of T1D, and they may begin months before marked weight-
loss and debilitation, which in turn are then followed by ketoacidosis (Cahill Jr. & 
McDevitt, 1981) if left untreated. At the onset of T1D, there is a marked reduction 
of β-cells (Conget et al., 1993), but often even in long-lasting T1D some β-cells 
remain functional and this can be detected by measuring C-peptide (Steck et al., 
2017). The higher the C-peptide level is, the more proinsulin secretion increases with 
meal stimulation (Sims et al., 2019). 
2.2.6 Complete β-cell destruction 
The β-cell loss is not linear as some β-cells are regenerated, but eventually the 
process will come to its final stage, and no C-peptide can be measured (Akirav et al. 
2008). Some proinsulin secretion remains even after C-peptide is undetectable and 
the last sign of complete β-cell destruction is that proinsulin stimulation by meals is 
blunted (Sims et al., 2019). 
2.3 Vitamin D 
Vitamin D is a collective term for a family of closely related seco-steroids. As 
illustrated in Fig.2, 7-dehydrocholesterol (7-DHC), also known as pro-vitamin D3, 
undergoes photolytic conversion in the skin to pre-vitamin D3, which then enters the 
bloodstream as vitamin D3, also known as cholecalciferol. Vitamin D3 can also be 
indigested from a variety of animal-based food. Other nutritional source of vitamin 
D are certain fungi and sprouts, which contain vitamin D2, also known as 
ergocalciferol. These compounds are biologically inactive, but they are hydroxylated 
in the liver to 25-hydroxyvitamin D (25[OH]D), which is the storage form of this 
vitamin. There is no significant storage of vitamin D in the liver of mammals and 
Marjaana Mäkinen 
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instead the storage form is rapidly released by the liver into the blood, where it 
circulates with a biological half-life of approximately 12-19 days. Approximately 85 
% of 25(OH)D is bound to vitamin D binding protein (DBP), 15 % to albumin and 
0.03 % is in free form. A small proportion of 25(OH)D that is bound to DBP becomes 
further hydroxylated, mainly in the kidneys, to the highly potent calciotropic 
hormone 1,25-dihydroxyvitamin D (1,25[OH]2D). The production of 1,25(OH)2D is 
tightly regulated and its serum half-life is only 4-6 h (Wootton, 2005). Macrophages 
and other cells are also capable of hydroxylating 25(OH)D into 1,25(OH)2D, so that 
it can be produced in higher concentrations locally in the tissues (Mathieu & 
Badenhoop, 2005).  
 
Figure 2. A simplified illustration of the vitamin D metabolism. Under ultraviolet B (UVB) radiation 
7-dehydrocholesterol converts to previtamin D3 in the skin and further to vitamin D, 
which can also be obtained from food and supplements. It enters the bloodstream, binds 
to vitamin D binding protein (DBP), is transported to the liver and converted to 25-
hydroxyvitamin D (25[OH]D), which is the major circulating metabolite. Some of the 
25(OH)D is transported to the kidney and hydroxylated into 1,25-dihydroxyvitamin D 
(1,25[OH]2D, which is the active metabolite. The 1,25(OH)D then binds to vitamin D 
receptors (VDR) and the excess is transformed into a more soluble compound, 1,24,25-
trihydroxyvitamin D (1,24,25{OH]3D), which is then secreted into bile. 
Review of the Literature 
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2.3.1 Determining 25-hydroxyvitamin D concentrations in 
serum samples 
The knowledge related to vitamin D metabolism and its clinical importance has 
increased explosively during the last decades, mainly because of commercially 
available immunoassays. However, getting reliable 25(OH)D results has been 
troublesome. 
Immunoassays can always be challenging (Hölzel, 1991), but the major problem 
in measuring 25(OH)D is attributable to the molecule itself. It is hydrophobic, exists 
in two forms, 25(OH)D2 and 25(OH)D3, and it is especially vulnerable to matrix 
effects. The matrix factors affect the ability of the binding agent, antibody, or DBP 
to associate with 25(OH)D in the sample or standard in equal fashion. DBP is more 
susceptible to these matrix effects than antibodies. (Hollis, 2004) 
Marked variability was observed in serum 25(OH)D measurements between 
laboratories early on (Binkley et al., 2004). No central authority has determined 
which cut-off points to use, so that a single individual may be deemed deficient or 
sufficient depending on the laboratory and many laboratories use much higher cut-
off points than the Institute of Medicine committee suggests (IOM, 2010). The 
international Vitamin D External Quality Assessment Scheme (DEQAS) was set to 
help verify the results obtained from different laboratories and it has been monitoring 
the performance of 25(OH)D assays since 1989. It has grown to comprise over 1000 
registered participants in 56 countries (Binkley & Carter, 2017). Each participant 
receives five serum samples four times a year, measures the 25(OH)D 
concentrations, sends back the results and reports what method was used. The All-
Laboratory Trimmed Mean (ALTM) is then calculated from all the results received 
and it has proven to be a good surrogate for the “true” total 25(OH)D target value 
produced by gas chromatography-mass spectrometry (Carter et al. 2004a). The 
laboratory then receives a certificate if it meets the performance target, which was 
initially to get 80 % of the results within ± 33 % of the ALTM (Carter et al., 2004b) 
and later 80 % within ± 30 % of the ALTM (Carter et al., 2010). Even though the 
performance target was quite wide, only 52 % of the participants met the criteria in 
2000, and 59 % in 2003 (Carter et al. 2004a). 
2.3.2 Sources of vitamin D 
Sun is a major source of vitamin D due to ultraviolet (UV) wavelengths of 20-315 
nm causing skin to produce a biologically inert precursor of vitamin D, 7-DHC, 
which is converted into provitamin D3 by body heat (Holick, 2009). Sun alone is not 
always enough, as vitamin D deficiency and rickets is not uncommon even in the 
sunniest of countries, such as Kenya (Jones et al., 2018). Natural sources of vitamin 
D include fish, meat, dairy products, eggs and certain mushrooms (Kiely & 
Marjaana Mäkinen 
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Cashman, 2018). Not all fish, for example tuna and saithe, contain vitamin D, but 
many popular fish in Finland, such as pikeperch, rainbow trout, salmon, perch, baltic 
herring and whitefish, contain substantial amounts of it, 8-22 µg/100g, while other 
sources contain significantly less, as eggs for example contain 2.2 µg/100 g (Valtion 
ravitsemusneuvottelulautakunta, 2010). 
2.3.2.1 Vitamin D recommendations in Finland 
As was stated already in 1960’s, it has long been known that children need 
vitamin D for healthy growth, but at the same time there has been concerns over the 
negative effects of an overdose. The recommendation was to give 2000 IU/day in 
supplements from the age of two weeks until the age of two years. This was 
considered safe and sufficient, but if fish liver oil was used, 1600 IU/day was 
sufficient and it could be given to children older than two years of age if needed. 
(Hallman et al. 1964) 
In the 1987 Finnish Nutrition Committee report, less vitamin D supplements 
were recommended than in the 1960’s; 10 µg (400 IU) per day throughout the first 
year of life and for growing children during the “dark period of the year”, which was 
not defined in detail. The daily recommended intake for children was 10 µg and 5 
µg (200 IU) for all adults, which had to include pregnant and breastfeeding women 
although they were not mentioned, and it was stated that intake should be adjusted 
to sunlight exposure. (Valtion ravitsemusneuvottelulautakunta, 1987)  
In the 1998 Finnish Nutrition Recommendations 10 µg/day was the appropriate 
vitamin D intake for children from two weeks until three years of age and for 
pregnant and lactating women, and for children between the ages four and ten years, 
5 µg/day was regarded sufficient. (National Nutrition Council, 1999). In the longer 
version of the report in Finnish it was explained that vitamin D is needed to prevent 
rickets and for that reason 10 µg/day was recommended for children with dark skin 
type during winter. Tolerable upper limit for average daily intake of vitamin D was 
set at 50 µg (2000 IU). (Valtion ravitsemusneuvottelulautakunta, 1998) 
Importantly, in 2003 it was noted that people in all age groups were getting 
inadequatly vitamin D. The groups needing the same special attention small children 
had been receiving were pregnant and lactating women and the elderly (> 61 years), 
and they were all recommended a dose of 10 µg/day, i.e. twice the amount that young 
adults were recommended to receive. The recommendation was thus the same as it 
had been five years earlier, but it was admitted that vitamin D supplements were 
needed during winter to achieve the recommendations. (Valtion ravitsemus-
neuvottelulautakunta, 2003) 
After 2003 there have been only small changes over the years, as in the latest 
general Finnish nutritional recommendations suitable vitamin D intake was10 
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µg/day from two weeks to two years of age, 7.5 µg/day (300 IU) for children between 
the ages of 2 an 18 years of age, 10 µg/day for pregnant and lactating mothers and 
20 µg/day for the elderly. Tolerable upper daily limit was set at 100 µg (4000 IU) 
for adults and 50 µg for children. (Valtion ravitsemusneuvottelulautakunta, 2014)  
According to EU regulation 2016/127 baby formulas, as well as baby porridges 
and gruels, are fortified with significant amounts of vitamin D (The European 
Comission, 2016) and thus use of vitamin D supplementation should be adjusted 
according to the amount of formula used (Valtion ravitsemusneuvottelulautakunta, 
2018). Tolerable upper daily limit is set at 25 µg (1000 IU) for babies between the 
ages of 0 to 6 months and 35 (1400IU) µg for babies between 6 and twelve months 
(Valtion ravitsemusneuvottelulautakunta, 2018). 
It should be stated that The Finnish Nutrition Recommendations are directed by 
definition for groups of healthy, fairly active people and may not always be ideal for 
every individual (National Nutrition Council, 1999). 
2.3.2.2 Vitamin D fortification of foodstuffs in Finland  
Systematic vitamin D fortification began in 2003 when it was noted that although 5 
µg per day was estimated to be enough, many people did not get that much from 
food during winter, as they ate les fish than was recommended. The fortification was 
0.5 µg/100 ml for liquid milk products and it was agreed upon in collaboration with 
the major dairy companies. (Valtion ravitsemusneuvottelulautakunta, 2003) In 2010 
the fortification was increased to1 µg/100 ml for liquid milk products and 20 µg/100 
ml for fat spreads (Valtion ravitsemusneuvottelulautakunta, 2010). 
2.3.3 Factors associated with serum 25(OH)D 
concentrations 
There are some differences of opinion about the optimal 25(OH)D concentration, 
although some views remain the same. Vitamin D deficiency is generally linked  
with osteomalacia, vitamin D depletion with osteoporosis, secondary 
hyperparathyroidism and calcium malabsorption, vitamin D sufficiency with skeletal 
health and eucalcemia, and vitamin D toxicity with hypercalcemia (Morris, 2005). 
Circulating 25(OH)D levels of 20-29 nmol/l are required in preventing rickets 
(Whiting & Calvo, 2005), 50-80 nmol/l can be considered satisfactory (Lamberg-
Allardt, 2006) and levels closer to 75-80 nmol/l may be needed to fully support both 
endocrine and autocrine functions (Whiting & Calvo, 2005). This means that the 
canonical function of vitamin D, i.e. optimizing intestinal calcium absorption, is fully 
expressed, elevated parathyroid activity is minimized and osteoporotic fractures are 
reduced when serum levels are approximately 80 nmol/l (Heaney, 2005). Skin type 
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determines the amount of UVB radiation required for sufficient 25(OH)D 
production, and it is in the range of 20-80 % of the personal sunburn threshold dose 
(Shih et al., 2018). The same amount of UV radiation causes a more significant 
increase in 25(OH)D concentration in people with light skin than in people with 
darker skin, even when they have a higher baseline concentration (Felton et al., 
2016). Using sunscreens is an easy way to block the cutaneous absorption of UVB 
radiation and vitamin D synthesis for all skin types (Matsuoka et al., 1987). 
2.3.3.1 Seasons 
As UVB radiation is a major source of vitamin D, seasons and sunlight exposure are 
major factors influencing circulating 25(OH)D concentrations, especially near the 
polar regions. General clinical observation in the past was that rickets was common 
in spring but rare in autumn (Maxwell, 1994). In Finland the mean 25(OH)D 
concentrations dropped from 82.5 nmol/l in the summer to 36.3 nmol/l in the winter 
(Savolainen et al. 1980) and in Norway the concentrations were roughly 50% higher 
in late summer compared to late winter (Moan et al., 2005). In Finland the summer 
values were somewhat lower in the elderly (Savolainen et al., 1980) and also in 
Norway it was discovered that the 25(OH)D concentrations were lower and the 
seasonal variation was greater in the young than in people over 30 years of age 
(Porojnicu et al. 2007). Seasonal variation is seen even in higher 25(OH)D 
concentrations, for example in a British study, where the mean concentration was 
already quite high, 72.5 nmol/l (Berry et al. 2011).  25(OH)D concentrations were 
significantly higher in Italians compared to Estonians both in winter (December-
February) and in summer (July-August) (Cutolo et al., 2006). 
2.3.3.2 Body mass 
It has long been known that in general, the higher the body mass index (BMI) of a 
person, the lower the serum 25(OH)D concentration (Szternel et al. 2018), whereas 
the 1,25(OH)2D does not differ significantly between obese children and controls 
(Reinehr et al., 2007). Weight loss leads to a significant increase in 25(OH)D levels, 
but less than would be expected if all 25(OH)D would be mobilised from the lost fat 
tissue into circulation, suggesting that some of it is converted into inactive 
metabolites and secreted (Pannu et al. 2016).  The low levels have been speculated 
to be attributed to decreased exposure to sunlight in obese subjects due to limited 
mobility, their clothing habits, or the excessive deposition of vitamin D in adipose 
tissue, with little evidence. In some studies lifestyle factors have had a more 
significant effect on 25(OH)D concentrations in children than their body 
composition (McVey et al., 2019). Recently, it has been shown in mice, that the 
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expression of the enzyme CYP2R1 responsible for 25(OH)D hydroxylation is 
reduced in obesity leading to decreased circulating 25(OH)D concentrations (Roizen 
et al., 2019). The interaction between body mass and vitamin D may also be inverse, 
as low maternal 25(OH)D concentrations were associated with increased body 
weight and thus increased BMI in children at the ages of one and three years (Neelon 
et al., 2018). 
2.3.3.3 Individual response to vitamin D intake 
The 25(OH)D increase following oral vitamin D3 supplementation varies greatly 
between people. In white adolescents, vitamin D intakes of 10 µg/day resulted in 6.7 
± 9.9 nmol/l difference in serum 25(OH)D concentrations from the baseline of 
roughly 50 nmol/l (49.2 ± 12 nmol/l)which means that in some individuals 10 µg 
was not enough in maintaining the previously obtained level, while in others the 
same amount caused the concentration to rise, and it took 20 µg/day to get a rise in 
25(OH)D concentrations in all study subjects (Smith et al., 2016). Similar results 
were obtained in Finnish infants, who received either 10, 30 or 40 µg of vitamin D 
daily, and 10 µg was not enough for all, but was for some (Holmlund-Suila et al., 
2012).  Some of the variation can be explained through differences in basal 25(OH)D 
levels, BMI and hormonal factors (Mazahery & von Hurst, 2015), but some of it is 
genetic. Especially genes involved with the hydroxylation of 25(OH)D, DBP 
(Soininen et al., 2018) and VDR (Barry et al., 2014) have an effect on 25(OH)D 
concentrations, but there are several other genes involved as well, widely distributed 
in the genome (Jiang et al., 2018). In general, genetic determinants cause less 
variation in 25(OH)D concentrations than environmental factors (D. Berry & 
Hyppönen, 2011), but in some populations the difference in 25(OH)D concentrations 
has been approximately 20 nmol/l between people with different genotypes (Ahn et 
al., 2010). Many VDR genes of peripheral blood mononuclear cells can be used as 
transcriptomic biomarkers for classifying individuals who possible benefit from 
additional vitamin D supplementation (Wilfinger et al., 2014). 
2.3.4 Hypervitaminosis D 
Very high, 200,000-300,000 IU/day doses of vitamin D cause hypervitaminosis D 
and hypercalcemia within a few weeks (Hallman et al., 1964). Accidental 
overfortification of milk in the U.S. in 1987- 1991 caused an outbreak of 
hypervitaminosis D with a median 25(OH)D concentration of 560 nmol/l (range: 
140-1740 nmol/l) and lead to death of two people (Blank et al., 1995). It is 
noteworthy that some people were symptomatic already with rather low  levels of 
25(OH)D, i.e. 140 nmol/l. at As some individuals are very sensitive to vitamin D, in 
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rare cases vitamin D intoxication is possible with recommended vitamin D intake 
(Waheed et al., 2018). With vitamin D fortification of foodstuffs and better 
compliance of recommendations regarding vitamin D supplementation, the 
25(OH)D concentrations have become very high in some individuals, up to 280 
nmol/l, in the traditionally low umbilical cord serum samples in Finland (Hauta-Alus 
et al., 2019). 
2.4 Vitamin D and type 1 diabetes in children 
When receptors for 1,25-hydroxyvitamin D were discovered in human leukocytes in 
the early 1980’s (Provvedini et al. 1983), it became clear that vitamin D had a role 
in human immunology. First the effects were seen in monocytes changing toward 
macrophage phenotype in the absence of 1,25(OH)2D (Provvedini et al., 1986) and 
when 1,25(OH)2D was found to regulate differentiation of T cell subsets CD4+ and 
CD8+ (Willheim et al., 1999) previously found important in the development of T1D 
(Hänninen et al., 1992), a direct link between T1D and vitamin D could be 
suggesteded.  
An indirect link could also be suggested, as low 25(OH)D concentrations have 
been associated with more frequent respiratory infections (D. J. Berry et al., 2011) 
and viral infections have been suspected to trigger T1D (Dotta et al., 2007).  
Moreover, children diagnosed with type 1 diabetes have been found vitamin D 
deficient (Svoren et al. 2009). In some studies vitamin D deficiency has been much 
more common in children with T1D than in controls (Bener et al., 2009), while in 
others there have been no differences (Garcia et al., 2007). Vitamin D deficiency has 
been more prevalent in diabetic subjects with albuminuria, as urinary DPB excretion 
is simultaneously increased (Thrailkill et al., 2011).  
2.4.1 25(OH)D concentrations and type 1 diabetes 
2.4.1.1 During pregnancy or at birth 
Low 25(OH)D concentrations during pregnancy are quite common all around the 
world (Bischoff-Ferrari, 2011; Cavalier et al., 2008; Clifton-Bligh et al., 2008; 
Eggemoen et al., 2016), and vitamin D deficiency is especially common if the mother 
has gestational diabetes (Eggemoen et al., 2018) or has dark skin type (Bodnar et al., 
2007). Recently it has been shown that maternal 25(OH)D concentrations have a U-
shaped association with cord serum insulin and C-peptide, which in turn may have 
an impact on glucose regulation and growth (Switkowski et al., 2019). 
As the 25(OH)D concentrations are somewhat higher during pregnancy in 
women originating in Western European countries with high paediatric T1D 
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incidence than in women living in the same area but who originate in developing 
countries and whose offspring has  similar or lower incidence (Agrawal et al., 2019; 
Eggemoen et al., 2016; The DIAMOND Project Group, 2006), it seems unlikely that 
low maternal 25(OH)D concentrations alone would increase the risk for T1D in the 
offspring. In a Norwegian cohort, with samples taken 1992-1994, a trend toward a 
higher risk for T1D was found with lower maternal levels of vitamin D during 
pregnancy (Sørensen et al., 2012), but the difference was no longer statistically 
significant after adjusting for DBP concentration, even though neither was the effect 
of DBP alone (Sørensen et al., 2016). In another cohort, with samples taken 1999-
2005, the same group found that low DBP concentration at birth, but not during 
pregnancy, was associated with increased risk of T1D and that increased 25(OH)D 
levels may lower the risk in certain VDR genotype (Tapia et al., 2019). By analysing 
neonatal blood spots, a small Italian study found no association between 25(OH)D 
levels and risk of T1D, except in an even smaller subgroup of migrant babies of 
mainly African origin, where the difference was small but statistically significant 
between cases (N=23) and controls (N=57) (Cadario et al., 2015). A Danish research 
group showed with a very large cohort (study population 331,623 individuals, of 
which 886 cases) that neonatal 25(OH)D status was not associated with a later risk 
of T1D (Jacobsen et al., 2016). The result was confirmed by a large Danish and 
Norwegian study, which found that maternal 25(OH)D measured during different 
trimesters or at birth were not associated with later risk of T1D in the offspring 
(Thorsen et al., 2018). In a Norwegian study it was shown that 1,25(OH)2D 
concentration is strongly correlated with 25(OH)D concentration 
In Finnish mothers, with samples taken during first trimester 1986-1989 and 
matched to the exact day they were taken, no difference was found in 25(OH)D 
concentrations between those whose children later developed T1D (mean 47.9 
nmol/l) and those whose did not (mean 47.7 nmol/l), but 70 % were vitamin D 
deficient or insufficient (Miettinen et al., 2012). 
2.4.1.2 Before onset of diabetes 
Alike pregnant mothers, children have low 25(OH)D levels all around the world; in 
countries with plenty of sunshine and low T1D incidence, such as Iran (Ardestani et 
al., 2010), China (Li et al., 2018), United Arab Emirates (Haq et al., 2018), Mexico 
(Acosta-Bendek et al., 2017), and also in Finland (Savilahti et al., 2016).  
It has been speculated that the low 25(OH)D levels are the reason why T1D 
incidence in children is globally rising, and for example in Poland the 25(OH)D 
levels used to be higher in children, but decreased over the past decades and were 
low in the beginning of this decade (Wójcik et al. 2018). However, the findings 
regarding an association between low 25(OH)D levels and risk of IA or T1D have 
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been contradictory. In many studies no association has been found between 
25(OH)D concentrations and risk of IA (Reinert-Hartwall et al., 2014) or T1D or 
both (Simpson et al., 2011), but there were some weaknesses in these studies, as the 
first study was small, with only 35 cases and 115 children in total (Reinert-Hartwall 
et al., 2014), and, although larger with 90 children developing T1D, 211 IA children 
and 2,686 controls, the latter defined IA already when just one autoantibody was 
present, and as only one sample was drawn each year after the child had turned two 
years of age, no seasonal variation could be taken into account (Simpson et al., 2011). 
In a study with 376 IA children and 1041 controls  high plasma 25(OH)D 
concentration was associated with lower risk of IA (Norris et al., 2018) and in 
somewhat smaller study with 108 IA, 244 T1D and 406 control children levels were 
lower in children with IA than in controls, with the largest difference in the summer 
levels and no samples from the cases before seroconversion  (Raab et al., 2014).  A 
study conducted in the U.S. military with 1000 adults who later developed T1D and 
1000 matched controls reported a 3.5-fold lower risk of T1D with a serum 25(OH)D 
concentrations of 60 nmol/l or higher, where only single sample per subject was 
drawn 1 month to up to 10 years before diagnosis (Gorham et al., 2012), which can 
be considered as a clear limitation. Additionally, in a study with 284 otherwise 
healthy children 25(OH)D concentrations ≤ 50 nmol/l were associated with impaired 
fasting glucose tolerance (Szternel et al., 2018). In a reasent international study of 
15 countries the 25(OH)D concentrations were lower in the case children (for IA 
mean 57.7 nmol/l, N=84, and for T1D mean 58,0 nmol/l, N=65) 18 months before 
seroconversion than in controls (mean 64.8 nmol/l for IA controls and 65.0 nmol/l 
vfor T1D controls), and for T1D children also at the age of 12 months (mean 70.1 
nmol/l vs. 75.9 nmol/l), but not at other time points (Miettinen et al., 2020).  
2.4.1.3 After diagnosis 
It seems to be a global phenomenon that the 25(OH)D concentrations are lower in 
paediatric patients with T1D than in controls. In a study of Australian children, 
25(OH)D concentrations were lower in the 56 T1D children (78.7 nmol/l) than in the 
46 unmatched controls (91.4 nmol/l) (Greer et al., 2013). In Egyptian children, 
25(OH)D concentrations were lower in the 120 T1D patients (35.5 nmol/l) than in 
their 120 controls matched for age, sex and ethnic origin (46.6 nmol/l), and even 
though the difference in the mean values may partly be due to the higher BMI of 
control children, the difference remained significant after adjustment with BMI 
(Abd-Allah et al., 2014). In Qatar vitamin D concentration was lower in the 170 T1D 
children (median 39.4 nmol/l) than in their matched 170 controls (42.6 nmol/l), but 
there were some differences in BMI and skin type between cases and controls (Bener 
et al., 2009). The mean serum 25(OH)D was lower in 296 Chinese children with 
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T1D (48.7 nmol/l) than in 295 controls matched for age and sex (57.9 nmol/l) and 
there was no statistically significant difference in 25(OH)D levels in 190 children 
with established T1D compared with 106 children with newly diagnosed T1D, but 
there was no data on BMI of these children (Liu et al., 2018).  
Also in Korean children and youth between six and twenty years of age, mean 
serum 25(OH)D was lower in 85 T1D patients (53.9 nmol/l) than in 518 controls 
(69.9 nmol/l), the deficiency was independent of sex, age and BMI, and the levels 
were not associated with duration of the disease, insulin dose, C-peptide or 
glycosylated hemoglobin (Bae et al. 2018). In a large study with 1,426 children and 
youth diagnosed with T1D,  lower 25(OH)D concentrations were associated with 
insulin resistance (The et al., 2013). In children glycemic control, duration of T1D, 
and age have been associated with vitamin D inadequacy in bivariate analysis of 128 
children with a mean age of 10.8 years (range 1.6-17.5), however, only age remained 
a significant predictor in multivariate analysis (Svoren et al., 2009). At the onset of 
T1D the 25(OH)D concentrations (mean 46.2 nmol/l, N=142) were inversely related 
with the severity of diabetic ketoacidosis (Savastio et al., 2016). Diabetic children 
with 25(OH)D concentrations ≤ 25 nmol/l showed higher insulin requirement and 
HbA1c than others (Savastio et al., 2016). In 129 Swiss children with T1D the 
majority was vitamin D deficient, especially during the winter, but neither age, 
calcium intake, duration of diabetes, HbA1c nor serum magnesium concentration 
associated with the 25(OH)D concentrations (Janner et al., 2010).    
Only two peripheral immune mediators, chemokine ligand 8 and leptin, were 
associated with 25(OH)D concentrations in newly diagnosed paediatric T1D patients 
(N=460), while 16 other peripheral immune mediators studied were not, and the 
25(OH)D concentrations were not statistically different from the controls, which 
were siblings to the patients (N=453) (Thorsen et al., 2017). 
25(OH)D concentrations were lower in newly diagnosed T1D patients (N=244) 
than in unmatched autoantibody-negative children (N=406) throughout the year and 
51% of children with T1D were vitamin D deficient (Raab et al., 2014). 
2.4.2 Vitamin D intake or supplementation and T1D 
2.4.2.1 During pregnancy  
Maternal vitamin D intake from food, but not from supplements, during pregnancy 
was associated with decreased risk of IA in the offspring (Fronczak et al., 2003). In 
a small Norwegian pilot study of 85 subjects and 1071 controls, a strong negative 
association between mothers taking cod liver oil during pregnancy and the risk of 
T1D in their children was found, and it was independent of multivitamin use (Stene 
et al. 2000), but in a larger Norwegian study with 545 cases and 1668 controls, the 
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use of cod liver oil or other vitamin D supplements during pregnancy were not 
associated  with T1D (Stene & Joner, 2003).  In a large Danish birth cohort study of 
children born in 1983-1988 found no evidence that vitamin D fortification of 
margarine would have an effect on the risk of T1D in the offspring (Jacobsen et al., 
2015). Vitamin D intake was not associated with the risk of advanced beta cell 
autoimmunity/T1D in offspring in the Finnish Diabetes Prediction and Prevention 
study (DIPP), where the maternal mean daily intake of vitamin D was 5.1 μg from 
food and 1.3 μg from supplements when10 μg was recommended (Marjamäki et al., 
2010). In the recently published international The Environmental Determinants of 
Diabetes in the Young (TEDDY) study, vitamin D supplementation during 
pregnancy was not associated with the risk of IA (Silvis et al., 2019).  
2.4.2.2 During childhood before the onset of T1D 
In a European study, vitamin D supplement use in early childhood was associated 
with a decreased risk of T1D (EURODIAB Substudy 2 Study Group, 1999). In a 
large Finnish birth-cohort study of children born in 1966 low vitamin D 
supplementation during the first year of life was associated with increased risk of 
T1D later in life (Hyppönen et al., 2001). In an American study no association was 
found between vitamin D intake and risk of IA or T1D (Norris et al., 2007; Simpson 
et al., 2011). In a meta-analysis the risk of T1D was significantly reduced in infants 
who were supplemented with vitamin D compared to those who were not, and infants 
using higher amounts were at a lower risk, when also cod liver oil was considered a 
vitamin D supplement (Zipitis & Akobeng, 2008). However, cod liver oil is also a 
source of fatty acids and dietary intake of omega-3-fatty acids has been associated 
with a reduced risk of IA (Norris et al., 2007), and also in the aforementioned large 
Norwegian study the use of cod liver oil, but not the use of other vitamin D 
supplements, during the first year of life showed association with lower risk of T1D 
(Stene & Joner, 2003). 
2.4.2.3 After T1D diagnosis 
In a British study, paediatric T1D patients who were vitamin D deficient (≤ 30 
nmol/l) and vitamin D insufficient (≤ 50 nmol/l) were supplemented with 150 µg 
(6000 IU) or 10 µg (400 IU), respectively, daily for 3 months, and this improved the 
HbA1c levels (Giri et al., 2017).  Vitamin D supplementation (25 µg = 1000 IU/day) 
improved glycaemic control in children with T1D (Savastio et al., 2016). These 
promising effects may be temporary of nature, as in another study where T1D were 
treated with 25 µg/day (1000 IU) of vitamin D, no differences in C-peptide, HbA1c, 
or insulin requirement were present after one year of follow-up (Napoli et al., 2013). 
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As some promising results were obtained with vitamin D, it was thought that 
maybe administering the active form of vitamin D, 1,25(OH)D2 directly would be 
even more effective, but this does not seem to be the case. When young adults with 
recently diagnosed T1D received 0.25 µg/day of 1,25(OH)D2 for 9 months, the 
treatment was found to be safe but ineffective, as it did not reduce loss of β-cell 
function or change the titres of autoantibodies (Walter et al., 2010). Similar results 
were obtained when Italian paediatric and adolescent recently diagnosed T1D 
patients were treated with 0.2 µg/day of 1,25(OH)D2, and followed-up for two years; 
no differences were found in levels of  A1C or insulin requirements and C-peptide 
levels dropped similarly in the untreated control group (Bizzarri et al., 2010).  
2.4.3 Vitamin D linked genetic polymorphism and T1D 
Already over a decade ago a common inherited variation of the vitamin D 
metabolism CYP27B1 gene encoding for the enzyme 1-α-hydroxylase was 
associated with increased risk of T1D in a British study of nearly 8000 patients and 
over 8000 controls (R. Bailey et al., 2007). The other studies have been smaller. In 
a meta-analysis of the early small studies it was concluded that VDR polymorphism 
BsmI has some association with increased risk of T1D, especially in Asian 
populations (Zhang et al., 2012). A large study with families from the U.K., Finland, 
Norway, Romania and the U.S. no association was detected between common 
sequence variation in the VDR gene and T1D (Nejentsev et al., 2004). 
In Kuwaiti Arab T1D children the frequency of variant alleles of VDR gene 
polymorphisms FokI and TaqI was significantly higher than in controls (Rasoul et 
al. 2019) and in Egyptian children VDR BsmI and FoxI polymorphisms were 
associated with T1D (Abd-Allah et al., 2014), while no difference in VDR 
polymorphism distribution in Australian children with or without T1D could be 
observed (Greer et al., 2013). 
In the TEDDY study where high plasma 25(OH)D concentration was associated 
with lower risk of IA, it was found that this association is further stratified by VDR 
polymorphism (Norris et al., 2018). VDR polymorphism alone was not associated 
with risk of IA in the DAISY study, but it was associated with the rate of disease 
development in IA positive children (Frederiksen et al., 2013) and the strength of 
association between VDR polymorphism and 25(OH)D concentration was found 
stronger in mothers of T1D children during pregnancy than in control mothers, 
emphasising the importance of in utero environment for the development of T1D in 
the child  (Miettinen et al., 2017a). 
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3 The Aims of the Present Study 
The aims of this study were to get an overall view of serum 25-hydroxyvitamin D 
(25[OH]D) concentrations in Finnish children, and to investigate the possible 
connection of the concentrations with T1D pathogenesis. 
The specific aims of this study were: 
*  To analyse 25(OH)D concentrations in healthy Finnish children in 
consecutive serum samples from the age of 3 months in 3- to 12-month 
intervals during different calendar years 
*  To analyse 25(OH)D concentrations in the follow-up samples of children 
who develop T1D, and in their carefully matched autoantibody-negative 
counterparts 
*  To find if there are differences in 25(OH) concentrations already at birth 
between children who develop islet autoimmunity (IA) or type 1 diabetes 
(T1D) and autoantibody negative children 
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4 Subjects and Methods 
4.1 Subjects and overview of the study cohorts and 
design 
All the subjects were born in 1994-2004 and participated in the Type 1 Diabetes 
Prediction and Prevention (DIPP) study, where new-born infants with HLA-
conferred susceptibility to T1D are recruited from the University Hospitals of Turku 
(60 ºN), Tampere (61 ºN) and Oulu (65 ºN), Finland. 
4.1.1 Healthy children (Study I) 
The sampling period of this study was limited to 1998-2006 and to the Turku area in 
order to avoid overrepresentation of young children and to limit variation due to 
location. The first serum samples were collected at the age of 3 months and at 3- to 
6-month intervals thereafter. In total, 5334 serum samples from 387 children (233 
boys, 154 girls) were measured for 25(OH)D.  
4.1.2 Children developing T1D and their controls (Study II) 
There were 3702 serum samples from 252 children in this study: 126 cases who 
developed T1D by the end of 2012, and 126 control children, matched pairwise for 
age (birth within one month), sex, study site, and HLA-DQB1. In the Turku cohort, 
the first serum samples were obtained at the age of 3 months followed by sample 
collection at 3-month intervals during the first 2 years after which autoantibody-
negative children were monitored at 6-month intervals. In the Tampere and Oulu 
cohorts the serum samples were drawn at the age of 3, 6, 12, 18, and 24 months and 
yearly thereafter, if they were autoantibody negative. If the participant 
seroconverted, the follow-up was changed to 3-month intervals in all the centres and 
the follow-up continued to the diagnosis of T1D. As the number of samples per child 
was different in the two groups due to the study protocol a sub-cohort from the full 
data set with a matching number of samples from each pair of children was 
established by selecting the samples closest to each other based on sampling dates to 
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enable further analysis. This restricted data set included 3060 samples from the same 
252 children.  
4.1.3 25(OH)D levels at birth (Study III) 
In the birth study there were 764 umbilical cord serum samples from 764 DIPP study 
participants: 133 case-control pairs in the Turku cohort, 137 in the Oulu cohort and 
112 in the Tampere cohort. Case children comprised two groups; 250 children, who 
were diagnosed with T1D by the end of July 2016 (T1D+) and 132 children, who 
were IA positive for multiple (≥2) autoantibodies, but did not progress to overt T1D 
by the end of the study period (IA+). The cases were included based on the 
availability of samples and one control subject was selected for each case child. All 
control subjects (T1D- and IA-) remained autoantibody-negative and non-diabetic 
throughout the follow-up, and they were pairwise matched for age (birth within 30 
days), sex and study centre.  
4.1.4 T1D criteria and ethical aspects 
The children were diagnosed with T1D according to the World Health Organisation 
criteria (World Health Organization, 1999). The three studies were conducted 
according to the guidelines of the Declaration of Helsinki. They were a part of the 
DIPP study that was approved by the Joint Commission on Ethics of the University 
of Turku and the Turku University Central Hospital (decision 1.2.1994 §228). 
Written informed consent for the DIPP study was obtained from all subjects and/or 
their guardians as explained in (Kupila et al., 2001). 
4.2 Methods 
4.2.1 Genetic screening 
All children in the study were genetically screened for an increased risk of T1D using 
HLA-DQB1 alleles in the laboratory of Immunogenetics, University of Turku, 
Turku, Finland. For genetic screening droplets of umbilical cord blood were dried 
on filter paper, from which DNA was directly amplified by PCR, as previously 
described (Sjöroos et al. 1995). During 1994-2004 HLA-DQB1*02/0302 was 
considered high-risk genotype and the HLA DQB1*0302/x; *0301, *0602, *0603, 
and for male children in the Turku cohort also *02, were considered moderate-risk 
genotypes (Hermann et al., 2003; Ilonen et al., 1996; Nejentsev et al., 1999), and the 
children carrying them were then eligible for the prospective follow-up study.  
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4.2.2 Nutrition during pregnancy 
Maternal dietary data of the eighth month of pregnancy was collected by a validated 
food frequency questionnaire after the birth of the child, as previously described 
(Marjamäki et al., 2010).  
4.2.3 Blood and serum samples 
Mixed arterial/venous umbilical cord blood was collected in the delivery room. For 
genetic screening, fresh blood was brought to the laboratory of Immunogenetics, 
where 4 blood drops from each child were dried on a filter paper (Schleicher & 
Schuell, Dassel, Germany). Disks of 3 mm in diameter of these blood spots were 
punched out directly onto 96-well PCR plates (Thermowell, Corning Costar, the 
Netherlands). DNA was amplified by PCR and hybridised with europium, terbium 
or samarium lanthanide chelates, which were then detected with time-resolved 
fluorometry (VICTOR fluorometer, Perkin-Elmer Finland, Turku, Finland) (Sjöroos 
et al., 1995). Analgesic lidocaine-prilocaine cream (EMLA, Astra Zeneca, Sweden) 
was used before venepuncture for serum samples. Serum was extracted, divided into 
3 to 9 aliquots, and stored at -70 to -85 ºC.  
4.2.4 Immunological methods 
T1D-associated autoantibodies were analysed in the Research Laboratory, 
Department of Paediatrics, University of Oulu, Finland. Islet cell antibodies (ICA) 
were used as the primary screening tool for beta cell autoimmunity until the end of 
2002. If a child was ICA positive or progressed to clinical type 1 diabetes during the 
follow-up, all their preceding and subsequent samples were also analysed for insulin 
autoantibodies (IAA), for the 65 kDa isoform of GAD autoantibodies (GADA) and 
for islet antigen 2 autoantibodies (IA-2A). Since 2003, all samples were analysed 
directly for ICA, IAA, GADA and IA-2A for study participants born in 2003 and 
later. 
ICA were measured using a standardized indirect immunofluorescence staining 
method on frozen human pancreas sections from a blood group O donor, as 
described previously (Bottazzo et al., 1974). The cut-off limit for ICA positivity 
was 2.5 Juvenile Diabetes Foundation units (JDFU). The biochemical 
autoantibodies IAA, GADA and IA-2A were analysed with radiobinding assays on 
96-well microplates, as previously described (Kulmala et al., 1998; Savola et al., 
1998a; Savola, et al., 1998b; Williams et al., 1997). Titres of the biochemical 
autoantibodies were expressed in relative units (RU). RU were based on a standard 
curve prepared for each assay plate using MultiCalc software (PerkinElmer Life 
Sciences, Wallac, Turku, Finland). Cut-off values for positivity were defined as 
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the 99th percentile levels in 370–374 healthy Finnish children: IAA, 3.48 RU for 
the new method starting 2000 (Pöllänen et al., 2017) and 1.56 RU for the old 
method before 2000 (Hämäläinen et al., 2002); GADA, 5.36 RU; IA-2A, 0.43 RU. 
All the initially ICA-positive samples were retested to confirm positivity, as were 
the study samples with titres between the 97th and 99.5th percentiles of the 
reference population values.. The disease sensitivity of the old IAA microassay 
was 14%, and the specificity was 100% in the 2001 Diabetes Autoantibody 
Standardization Program (DASP) Workshop. Subsequently, the IAA assay was 
optimized, resulting in a disease sensitivity of 30%, the specificity remaining at 
100%, based on a blinded reanalysis of the 100 DASP Workshop samples. The 
intra-assay coefficient of variation was 7%, and the interassay coefficient of 
variation was less than 9% in the IAA assay (Kimpimäki et al., 2002). Based on 
the 2005 DASP Workshop, the disease sensitivity values for the new IAA, GADA 
and IA-2A assays were 58%, 82%, and 72 %, respectively, while the corresponding 
disease specificity estimates were 98%, 96%, and 100 %. In the 2007 DASP IAA 
Affinity Workshop, the combination of the assay for the IAA level with the affinity 
assessment increased the disease sensitivity and specificity of the IAA assay to 90 
% and 100 %, respectively (H. Siljander et al., 2009). The time point for 
seroconversion was defined as the date of the first autoantibody-positive sample. 
Confirmed autoantibody positivity was defined as positivity for at least one 
autoantibody in at least two consecutive samples. 
4.2.5 Determination of serum 25(OH) D 
25--hydroxy-vitamin D concentrations were measured in serum using commercial 
25-Hydroxy Vitamin D EIA analysis kit (Immunodiagnostic Systems Limited, 
UK).  As every drop of the DIPP serum samples is very precious and could be used 
for a number of other analysis, the protocol was optimized to require only 10 µl 
instead of the original 25 µl of serum, in collaboration with the kit manufacturer. 
The changes affected only the first few steps as the samples were diluted into 400 
µl of sample buffer containing biotin-labelled 25(OH)D antibody, on a 1.2 ml 
polypropylene 96-well plate (ABgene, Epson, UK), instead of 1 ml in separate 
sample tubes. This made it possible to use a 12-channel pipette (BioHit, Finland) 
and to get the samples on the analysis plate almost simultaneously, thus minimizing 
the differences on incubation time and assay drift. Standards were added in 
duplicate but controls and samples in single wells, so that 80 samples were fitted 
per plate.  
Standards with seven different concentrations, two controls and all the samples 
were diluted with biotin labelled 25(OH)D. The diluted samples were incubated in 
microtitre wells coated with a highly specific sheep 25(OH)D antibody for two hours 
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at room temperature before aspiration and washing. Horseradish peroxidise labelled 
avidin was added and following a further washing step, colour developed using a 
chromogenic substance (TMB). The reaction was stopped with hydrochloric acid 
and the absorbance of the reaction mixtures read at 450 nm using Victor 
(PerkinElmer Finland). The developed colour intensity is inversely proportional to 
the concentration of 25(OH)D and the working range was from 0 to 418 nmol/l. The 
concentrations were calculated from the absorbance values obtained, using Wallac 
MultiCalc™ (PerkinElmer Finland). 
Since the only way for laboratories to demonstrate the accuracy of their results 
is to participate in an external quality assessment scheme (Carter, Carter, Jones, & 
Berry, 2004) also we participated in The International Vitamin D Quality 
Assessment Scheme (DEQAS) and the small participation fee was paid by the kit 
manufacturer (IDS Ltd, UK). Our results were in the acceptable range (using 50 
samples, the R2 was 0.72, R2 adjusted 0.71, correlation of estimates 0.9265)  from 
the All-Laboratory Trimmed Mean (ALTM) values, which has been considered a 
good surrogate for the “true” target values obtained by gas chromatography-mass 
spectrometry. (Tahsin-Swafiri et al., 2012). During our participation, the number of 
laboratories participating in 25(OH)D measurement in DEQAS increased from 121 
to 1119 making the ALTM results more reliable towards the end.  
All samples from each child, or case-control pair, were analysed with the same 
batch of kits whenever possible. This was challenging in work II, where the median 
number of samples per sample-matched pair was 20 (IQR 12-34), but even there the 
median number of batches was 1 (IQR 1-2) and the median number of different plates 
3 (IQR 1-7.25). The results obtained in 2005-2007 with the first four batches of kits 
were re-calculated according to the instructions provided by the kit manufacturer and 
verified by the kit importer (Biofellows, Helsinki, Finland).  
Both inter and intra assay variations were calculated using four different samples 
which were measured ten times. Two batches of kits were used in the inter-assay 
variation measurement, but only one for each analyte, lot #53336 for the first two 
samples and lot #56128 for the second two samples. In the intra assay analysis the 
mean concentration of 25(OH)D in the first sample was 24.1 nmol/l and the CV was 
4.6 %. In the second sample the mean concentration was 52.3 nmol/l and CV 5.2 %, 
in the third 89.0 nmol/l and CV 7.1 %, and in the fourth 87.3 nmol/l and CV 7.4 %. 
In the inter assay analysis the mean 25(OH)D concentration was 42.3 nmol/l, CV 9.6 
% for the first sample and 112.2 nmo/l and CV 7.4 % for the second sample of the 
first batch of kits. In the second batch the means were 21.9 nmol/l and 92.2 nmol/l 
and the CVs 10.3 % and 7.0 %, respectively. The sensitivity reported by the kit 
manufacturer was 5 nmol/l. 
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4.2.6 Collection of clinical data  
During the early years of the DIPP study, the study nurses have recorded information 
on clinical well-being of the children by hand on paper files by each visit. These files 
have then been transformed in an organized manner to the electronic forms of the 
DIPP databases and the original files have been stored under lock and key. 
Additional information was obtained from Turku, Oulu, and Tampere University 
Hospital records and National Institute of Health and Welfare.    
4.2.7 Statistical methods 
In the first study (I) the statistical analyses were carried out using chi-square tests 
and mixed model analyses, where subject was used as a random effect. The effect of 
sample year was studied separately in two age groups (over/under 2 years) and 
together with sample month and sex were used as independent variables. The 
associations were further studied by adding the interaction between the sample year 
and sex as independent variables. Statistical analyses were performed using SAS for 
Windows version 9.3. P-values lower than 0.05 were considered statistically 
significant. 
In the second study (II) the associations between 25(OH)D concentrations and 
case-control status were studied using conditional logistic regression. Associations 
between response variable, i.e. 25(OH)D concentrations and various predictor 
variables were studied using mixed models with the subject as a random variable. 
The results were adjusted for sex, age, sample month and year when appropriate. 
Numbers of samples in each group of the original data were compared using 
independent samples t-test. All statistical analyses were performed with SAS for 
Windows version 9.3. For all analyses, statistical significance was defined as P ≤ 
0.05.  
For the third study (III) season of birth and study centre were used as adjusting 
factors in all analysis. Log-transformation was used when necessary in analyses 
requiring normal distribution. Possible confounding factors were controlled for by 
adding background variables to the statistical models. Statistical analyses were 
performed with JMP Pro 12.0.1 and SAS for Windows version 9.4 using multi-way 
analysis of variance and Fisher’s exact test for categorical variables. The value of P 
< 0.05 (two-tailed) was taken to indicate statistical significance. 
For additional analysis on intra-assays, DEQAS results, and on work III, SPSS 
version 25 for Windows, JMP Pro 12.0.1 and R version 3.5.1 were used. 
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5 Results 
5.1 Serum vitamin D in healthy children 
Mean serum 25(OH)D levels were markedly lower in healthy children during the 
first period (years 1998-2002) than during the second (years 2003-2006) (69.3±1.0 
nmol/l vs. 84.9±1.3 nmol/l, respectively, P<0.001) in both genders (Publication I, 
Figure 1; Table 1). The mean difference between the periods was 15.7±1.3 nmol/l 
(P<.001). Seasons had a large effect on the 25(OH)D concentrations with peak 
values in late summer and the lowest values in late winter (Publication I: Figure 1; 
P<0.001) during both of the time periods. Young infants (<2 years) had higher 
25(OH)D concentrations than older children (Publication I: Table 1). Importantly, 
the frequency of children with low serum 25(OH)D levels (< 50 nmol/l) was almost 
halved from 1998-2002 to 2003-2006 (37.3 % versus 69.9 %; P <0.001). Similarly, 
the frequency of severe vitamin D deficiency (<25 nmol/l) was significantly lower 
after 2002 than before (2.7% vs. 7.7%; P=0.005). 
5.2 Serum vitamin D and development of type 1 
diabetes 
Distibution of the 25(OH)D concentrations at different age points was very similar 
in cases and controls as shown in the original publication II, Figure 1, and no 
statistically significant differences were observed. The median 25(OH)D 
concentrations were in the inadequate range of 50 to 75 nmol/l (Roizen et al. 2013) 
in both  cases and controls. In the full data set  the median 25(OH)D concentration 
was 66.6 nmol/l (range 14.0-262.8) in cases and 67.4 nmol/l (range 19.9-213.0) in 
controls (P= 0.56). Also in the restricted data set with matched samples from cases 
and controls they had very similar (P= 0.78) median concentrations (66.7 nmol/l 
[range 18.8-262.8] and 68.0 nmol/l [range 19.9-213.0], respectively). Month, year 
and the age of the child at sample draw had each a significant influence on 25(OH)D 
concentrations (P<0.001) both in the full and restricted data sets. 
The median 25(OH)D concentration were highest in Turku, approximately 70 
nmol/l, and lowest in Oulu, approximately 50 nmol/l. In Tampere the median 
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concentration were around 55 nmol/l in all groups. The differences between the 
centres were statistically significant in both the full and restricted data set (P <0.001). 
In the full data set 10.3 % of children had at least one sample in the range of 
severe vitamin D deficiency with concentrations below 25 nmol/l (Kull et al. 2009), 
but the difference between cases (17 children) and controls (9 children) was not 
statistically significant (P=0.10) and the situation was very similar in the restricted 
data set, where the proportion was 9.5 %, 15 cases vs. 9 controls (P=0.19). None of 
the children had 25(OH)D concentration below 25 nmol/l in more than 50 % of the 
samples. 
There was no correlation between 25(OH)D concentrations and the age of a case 
child at seroconversion for autoantibodies (P=0.79) or the age of disease 
manifestation (P=0.13). The 25(OH)D concentrations were similar before and after 
seroconversion, when adjusted for sample month, sample year, age of child at sample 
draw and sex (P=0.22) (Publication II: Figure 3) and when compared to controls 
before (P=0.35) or after seroconversion (P=0.23). There was neither any correlation 
of 25(OH)D concentrations with the number of autoantibodies present (Publication 
II: Suppl. Fig. 1), nor with the titres of the biochemical autoantibodies, GAD 
(P=0.40), IA2A (P=0.35), and IAA (P=0.46), when adjusted for sample month, 
sample year, age of child at sample draw and sex (Publication II: Suppl. Fig. 2).  
Since body mass index (BMI) may affect circulating 25(OH)D concentrations, 
we analysed the BMI in all children (Publication II: Table 1).  As BMI is dependent 
on age and sex of the child (Cole et al. 2000), it is difficult to take it into account in 
analysis when analysing different number of samples in growing children. We 
overcame this issue by first analysing the median age of the BMI data and it was 
similar between the groups (P=0.21). The median BMI was also the same in cases 
and controls (P=0.65), so it does not distort the results. There was an inverse 
association with BMI and the 25(OH)D concentrations; when BMI increased with 1 
kg/m2, median 25(OH)D concentration decreased with 1.3 nmol/l, similarly in cases 
and controls (P=0.57).  
5.3 Serum vitamin D at birth 
The median 25(OH)D concentrations in cord serum were essentially the same 
between the study groups (P=0.70). Most of the cord serum samples were below 50 
nmol/l, so that 88 % of the study children had suboptimal (Lamberg-Allardt et al. 
2013) vitamin D levels. As in older children, serum 25(OH)D concentrations were 
statistically significantly affected by year (P=0.001), month of birth (P=0.002) and 
study centre (P=0.03), so that the children of the Oulu centre (65°N) had significantly 
lower levels than the children in Turku (60°N) and Tampere (61°N) centres, but not 
by sex (P=0.64). The children were born evenly around the year: 210 children were 
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born in the winter, 182 in the spring, 187 in the summer, and 185 were born in the 
autumn. 
The basic characteristics were similar between the study groups T1D+, T1D-, 
IA+ and IA-, except that as could be expected (Ziegler et al., 2013), the T1D+ 
children seroconverted to autoantibody positivity at an earlier age than IA+ children, 
and the follow-up time was shorter in the T1D+ group due to the design of the study. 
The median age at the diagnosis of T1D was 6.7 years and the median age at 
seroconversion to autoantibody positivity in the T1D+ group was 2.0 years and 4.0 
years in the IA+ group (N=132). The 25(OH)D concentrations were not associated 
with the age at T1D diagnosis (P=0.53) nor with the age of seroconversion to 
autoantibody positivity (P=0.72).  
There were no statistically significant differences in 25(OH)D concentrations 
between T1D+ and IA+ groups positive for different number of autoantibodies 
(P=0.38 for all autoantibodies, P=0.32 for biochemical autoantibodies).  
No differences were found in 25(OH)D concentrations between the groups of 
cases and their matched 97 controls in a sub-cohort defined by the first appearing 
persistent biochemical autoantibody (P=0.61 for IAA and P=0.51 for GADA).  
HLA-DQB1 classification (moderate risk, high risk) was not associated with 
25(OH)D concentrations (P=0.57), and neither were the extended HLA-groups (non-
increased risk, slightly increased risk, moderately increased risk, and highly 
increased risk in HLA-DR/DQ) (P=0.46).  
The age of the mother at the time of birth was positively associated with 
25(OH)D concentration (P=0.002) in cord serum, so that the concentration increased 
by approximately 0.05 nmol/l for each additional year. The median age of the mother 
was 29.8 (IQR 26.6-33.6) years. The ponderal index of the child, calculated as 
weight in kg per height3, was inversely associated with 25(OH)D concentrations 
(P=0.031), but there was no statistically significant association with either weight  
(P=0.29) or length (P=0.75) alone to 25(OH)D. Furthermore, the ponderal index did 
not correlate with the age of the mother (P=0.16).  
Nutrition during pregnancy 
Nutritional information on the eighth month of pregnancy was available in almost 
half (48%) of the study population, and the general characteristics of this 
subpopulation are presented in Publication III: Table 3.  
Intake of vitamin D during pregnancy showed a statistically significant 
association with 25(OH)D concentrations in all forms, from food (P<0.0001), from 
supplements (P<0.0001), and in total (P<0.0001). The energy intake was not 
associated with 25(OH)D concentration (P=0.27). 
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The age of the mother had a statistically significant association with 25(OH)D 
concentration also in this subpopulation with roughly the same impact (P=0.025), 
and the median age of mothers was similar in the subpopulation as in the entire 
cohort (29.3 years vs. 29.8 years).   Maternal age did not correlate with energy intake 
(P=0.64), vitamin D intake from food (P=0.22), intake from supplements (P=0.51), 
nor with total vitamin D intake (P=0.22).  
Interestingly, ponderal index of the baby was not associated with the 25(OH) 
concentration in this subpopulation (P=0.097) but its correlation with the age of the 
mother was close to significant (P=0.059) and it did not correlate with energy intake 
(P=0.34), vitamin D intake from food (P=0.30), from supplements (P=0.52), nor 
with total vitamin D intake (P=0.93).  
The total vitamin D intake during pregnancy was quite low, which is not 
surprising as there were only 20 % of the mothers who reported the recommended 
total vitamin D intake during pregnancy ≥ 10 µg per day and only 9 % used vitamin 
D supplementation (≥ 5 µg vitamin D/day). 
Additional analysis 
Another way of analysing the cord serum 25(OH)D concentrations in matched case-
control pairs was tested after the results were published. Conditional logistic 
regression analysis confirmed the results. Using the matched data set with the same 
number of samples from cases and controls unadjusted OR was 1.002 (95% CI 
0.989-1.015). Adjustment with the age of the mother changed the results only 
slightly to the positive side and OR was 1.014 (95% CI 0.986-1.044). Adding 
ponderal index to the model had an equally slight reverse effect: OR 0.970 (95% CI 
0.915-1.028).      
 39 
6 Discussion 
Vitamin D is crucial for human well-being and not surprisingly, evidence for positive 
evolutionary selection of genes linked with higher circulating 25(OH)D have been 
found in Northern populations (Kuan et al. 2013). With other type of genetic 
distribution the 25(OH)D concentrations may drop to dangerously low levels without 
vitamin D supplementation, and this is a problem especially with some immigrant 
populations. It seems that Northern populations have also evolved to survive on low 
serum 25(OH)D and our group found a difference in VDR genes within Finland, so 
that more efficient VDRA and VDRB genes, which increase receptor function and 
upregulate vitamin D-induced protein expression, had higher frequencies in the Oulu 
than in Turku region (Turpeinen et al., 2003). This might explain why the low 
25(OH)D concentrations measured in this study in the Oulu subjects seem to have 
so little observed adverse effects. 
Even though low 25(OH)D concentrations at birth (Publication III) or during 
childhood (Publication II) were not associated with the risk of T1D later in life, the 
low concentrations may have other adverse effects. Vitamin D deficiency during 
pregnancy increases risk of gestational diabetes independently of other factors 
(Wang et al., 2018). Low 25(OH)D levels near birth have been associated with 
several neurodevelopmental disorders later (García-Serna & Morales, 2019), with 
increased risk of multiple sclerosis (Munger et al., 2016), and high blood pressure in 
3-year olds (Petersen et al., 2017). In obese children, low 25(OH)D concentrations 
have been associated with markers of cardiovascular disease independently of other 
factors (Censani et al., 2018). 
There is some evidence that cord blood might not be predictive of postnatal 
immunity of the child and samples taken at three months of age would best represent 
the real set point where human immune system develops and is further modified by 
environmental factors (Olin et al., 2018). In this work the three-month samples were 
measured for 25(OH)D and analysed together with subsequent samples (II) and only 
umbilical cord serum samples were analysed separately (III). It seems unlikely that 
analysing 25(OH)D concentrations separately from the three-month samples would 
reveal something unique about the T1D progress. The cord serum samples were 
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analysed because they reflect the environment during the near past, i.e. during foetal 
development, and in that perspective, they are quite unique.  
It is noteworthy that expecting mothers did not use vitamin D supplementation 
during the study period, despite recommendations, and thus their 25(OH)D levels 
were very low (publication III), but they gave vitamin D supplementation to their 
babies, who then had higher 25(OH)D concentrations in the bloodstream, without 
any seasonal variation (publication II). The study period proved to be rather 
interesting as it happened to overlap with the Finnish vitamin D fortification 
program, which somewhat changed the nutritional status of the Finnish population 
regarding vitamin D. The first fortification step in 2003 (Valtion 
ravitsemusneuvottelulautakunta, 2003) made a marked difference in 25(OH)D levels 
in children, as we showed in publication I. However, it was not enough for pregnant 
mothers to meet the daily intake recommendations of vitamin D (Prasad et al., 2010) 
and that could be seen in publication III as well. In 2010 the fortification was doubled 
and this seemed to be enough for adults, as the mean vitamin D intake in women 
increased from 3 µg/day in 2002 to 18 µg/day in 2012, and in men from 5 µg/day to 
17 µg/day (Raulio et al., 2017). This, together with better compliance with the 
recommended vitamin D supplementation, reflected in the umbilical cord serum 
samples taken 2013-2014 so that mean concentration was 82.5 nmol/l (Hauta-Alus 
et al., 2019), some 50 nmol/l higher than we found during earlier years (1994-2004) 
in (Publication III). In children the difference was not all that prominent, as in 12-
month samples taken in 2013-2015 the mean 25(OH)D concentration was 98.9 
nmol/l (Hauta-Alus et al., 2019), roughly 25 nmol/l higher than the median for 1-
year-olds in publication II.  
The major strengths in this study lie within the design of the DIPP study; 
recruitment at birth over many years followed by the long closely monitored follow-
up period with abundance of both serum samples and clinical data of a large 
paediatric population of both sexes. To date this study provides the largest number 
of serum 25(OH)D measured in consecutive follow-up samples, which permits for 
the first time the analysis of the seasonal changes in serum 25(OH)D during different 
calendar years before and after the beginning of national vitamin D fortification 
program. In children developing T1D there were samples quite uniquely at three-
month intervals over many years before the onset of the disease, if the children were 
IA positive, and at three- to six-month intervals before the appearance of 
autoantibodies. It is also noteworthy that the children were born quite evenly around 
several calendar years, a feature which is not obtained in studies with short 
recruitment periods. 
When different DIPP centres are compared, in the Turku data set the major 
strength was that the serum samples were collected in six-month intervals in all 
autoantibody-negative children disregard of age, and the major weakness that limited 
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nutritional data have been collected. The Tampere and Oulu data sets were quite 
alike, with annual sampling of autoantibody-negative children and a good coverage 
in nutritional information during the eighth month of pregnancy. 
One of the strengths of this study was that the immunoassays were done in in 
well-designed batches in a single laboratory thus minimizing the variation (Snellman 
et al., 2010) using a method which is specific for total 25(OH)D concentration. The 
assay had some emphasis on 25 (OH)D3 as only 75 % of 25(OH)D2 is measured 
according to the kit manual.  However, it is important that it ignores other forms of 
vitamin D, such as 3-epi-25(OH)D, and thus simplifies interpretation of the results 
(Singh et al., 2006).  The function of 3-epi-25(OH)D is still unknown, but 
interestingly it can be found in all age groups and it is most abundant in neonates, as 
reviewed in (D. Bailey et al., 2013). Free 25(OH)D, a form not bound to VBP, was 
not measured, even though it might be of some importance and perhaps should be 
measured at least in individuals with altered DBP levels (Bikle et al. 2017). If a 
patient with T1D suffers from diabetic nephropathy, DBP is excreted in the urine 
and this may cause vitamin D deficiency commonly seen in diabetic patients 
(Thrailkill et al., 2011), and measuring free 25(OH)D would probably be beneficiary. 
In the development of T1D the role of the free form is quite unclear and as the 
subjects in this study did not have overt T1D, it is unlikely that they would have 
suffered from diabetic complications requiring measurement of free 25(OH)D. 
Much has been learned over the years, but the final conclusive environmental 
trigger or other factors behind diabetic autoimmunity and the development of T1D 
remain unknown. Families sometimes try to prevent T1D in children based on 
something they hear or read, and this seem to happen especially if the child has a 
first-degree relative with T1D (Baughcum et al., 2005). This in turn requires scrutiny 
from the follow-up studies, as it is necessary to know and to record what 
experimental preventive methods the family might be undertaking and take this into 
account as a variable in analysis or already in case-control matching. In the early 
years of the DIPP study there were some inconsistencies depending on study centres 
and even on individual study nurses on what questions were asked from the families 
and how the results were then marked on the papers, as no electronic records were 
used at the research clinics in the 1990’s. For this reason for example reliable data 
on vitamin D supplementation of the children starting from birth was not available 
in all children, which is one of the weaknesses of this study. 
The cohort in Publication II was large, but a larger cohort of children would have 
made it possible to divide it into different subgroups, for example those who 
developed T1D before/after the age of 2 or 4 years, those with vitamin D deficiency 
vs. those with vitamin D sufficiency at different age points. Now the power for these 
analyses was too limited. Another weakness of study II is the somewhat limited 
number of vitamin D deficient samples, so that there is not enough power to examine 
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the effects of long-term vitamin D deficiency in childhood.  It may also be considered 
a weakness of all of these studies that the possible variables affecting 25(OH)D 
concentrations, such as skin type, clothing habits, nutritional factors and supplement 
use of the children, or single nucleotide polymorphisms (SNP) of genes linked to 
vitamin D metabolism, were not assessed. In an earlier study it had been shown that 
VDR SNPs were not associated with the risk of T1D in the DIPP cohort (Turpeinen 
et al., 2003). We did some preliminary analysis (data not shown) including 484 
children with 6989 samples from the age of three months onwards, and there were 
277 children with one SNP analysed (CC 23, CT 127, TT 127) and 211 children with 
another SNP (29 GG, 113 GT and 69 TT). It was not revealed what SNPs these were 
in order not to look for a specific result in the analysis. More SNPs were available in 
cases than in controls, but no association with 25(OH)D concentrations nor a 
statistically significant differences between cases and controls were found when 
sample month, age and sex of the child were included in the analysis, and so we 
decided not to proceed with this line of research. Some of the most interesting genetic 
variants are rare, and it would require a lot of children to get the groups large enough 
for detailed analysis. We decided to focus on the serum concentrations in consecutive 
samples over a long period of time. However, since then there have been some 
interesting findings. In a Finnish study maternal VDR variants were associated with 
the risk of T1D in the offspring (Miettinen et al., 2015) and in an international study, 
which included also Finnish children, increased childhood 25(OH)D was associated 
with decreased risk of IA, especially in some minor VDR alleles (Norris et al., 2018). 
Our aim was to study whether the concentrations are different in children who 
progress to IA or overt T1D compared to those who do not, irrespective of the 
possible mechanisms behind the differences. 
The genetic screening method in the DIPP study during the study years1994-
2004 relied on HLA-DQB1 and was later updated when more information on the 
genetic risk for T1D was available (Ilonen et al., 2016). This more detailed HLA-
screening which was used later would have improved the case-control match in 
Publication II and having more data on HLA-sequences might have been beneficial 
as HLA-B polymorphism has been associated with 25(OH)D concentrations 
(Miettinen et al., 2017b).  
There are many possible ways to analyse a nested case-control study like this 
and several methods were tested before selecting the ones we used in the 
publications. Autoantibody positivity and/or T1D were selected as end points and 
matched case-control pairs made the analysis more reliable in reducing the 
background noise. We tried area-under-the-curve –analysis, multiple of means –
analysis, chi-square tests, the published analysis and finally conditional regression 
analysis, and they all gave similar results: there were no differences between cases 
and controls in this data set.  
Discussion 
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We found that children who progress to IA or T1D have similar circulating 
25(OH)D concentrations as unaffected children, when they are carefully matched for 
age, geographic location in latitude of the living place, HLA-DQB1 risk, sex and 
time of blood draw. The results of this prospective study suggest that the 
development of T1D is not associated with marked changes in the vitamin D status. 
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7 Conclusions and Future 
Perspectives 
Conclusions 
*  Serum 25(OH)D concentrations were very low at birth 1994-2004, and maternal 
vitamin D intake was below recommendations during pregnancy.  
*  From the age of three months to the age of two years, no seasonal variation can 
be seen in 25(OH)D concentrations, and most children in the study cohort had 
sufficient vitamin D levels (>50 nmol/l).  
*  Vitamin D fortification of foodstuffs, mainly dairy products, which was begun in 
2003, increased serum 25(OH)D concentrations remarkably in Finnish children. 
*  Seasonal variation is prominent from the age of two years, and especially in 
1998-2003, many children were vitamin D deficient in winter.  
*  Seasonal variation of serum 25(OH)D is remarkable in the Northern latitudes 
and several samples are needed in order to determine the vitamin D status of an 
individual, as the individual variation is great as well. 
*  In matched case-control pairs, serum 25(OH)D concentrations were not directly 
associated with the appearance of diabetic autoantibodies nor with the risk of 
T1D, not at birth nor later in the childhood. 
Future perspectives 
*  The current vitamin D status of Finnish children should be studied. 
*  In future studies, adding data on genetic polymorphisms linked with vitamin D 
pathways on mothers, if not both parents, might deepen our understanding of 
vitamin D and the risk of T1D in the offspring. 
*  A detailed HLA-analysis providing more information on the genetic risk of T1D 
in children might further improve also our understanding on serum 25(OH)D 
concentrations. 
*  Large studies on serum concentrations of other vitamins and T1D, together with 
their genetic and environmental interactions, may shed more light on the 
complex interaction between vitamin D, different cell types of the immune 
system, and T1D.  
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